COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Real Life Safety and Efficacy of Vardenafil

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01215409
Recruitment Status : Terminated (Slow recruitment)
First Posted : October 6, 2010
Last Update Posted : May 19, 2014
Information provided by (Responsible Party):

Brief Summary:
In this uncontrolled, non-randomized, prospective, local post-marketed surveillance study, data are obtained on safety and efficacy of LEVITRA® in routine treatment of erectile dysfunction. The general objectives are to evaluate the product safety (primarily by recording adverse events), efficacy and patient acceptance.

Condition or disease Intervention/treatment
Erectile Dysfunction Drug: Vardenafil (Levitra, BAY38-9456)

Layout table for study information
Study Type : Observational
Actual Enrollment : 372 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Vardenafil in Routine Treatment of Erectile Dysfunction
Study Start Date : February 2008
Actual Primary Completion Date : November 2008
Actual Study Completion Date : November 2008

Group/Cohort Intervention/treatment
Group 1 Drug: Vardenafil (Levitra, BAY38-9456)
5 mg or 10 mg or 20 mg of Vardenafil, orally when necessary for 2 months

Primary Outcome Measures :
  1. General assessment of patients concerning efficacy and tolerability of vardenafil treatment [ Time Frame: 2 months ]

Secondary Outcome Measures :
  1. Time to first intercourse after intake of vardenafil [ Time Frame: 2 months ]
  2. Percentage of successful second intercourse within 24 hours [ Time Frame: 2 months ]
  3. Percentage of participants who are willing to continue treatment [ Time Frame: 2 months ]
  4. Number of participants with adverse events [ Time Frame: 2 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Primary care clinics

Inclusion Criteria:

  • Any adult patient (>/=18 years) with erectile dysfunction treated with LEVITRA®.
  • Patients must be able to give written informed consent for participation in the study after receiving detailed written and oral information prior to the study.

Exclusion Criteria:

  • Exclusion criteria must be read in conjunction with the product information (Package Insert).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01215409

Layout table for location information
Many Locations, Taiwan
Sponsors and Collaborators
Layout table for investigator information
Study Director: Bayer Study Director Bayer
Layout table for additonal information
Responsible Party: Bayer Identifier: NCT01215409    
Other Study ID Numbers: 14328
LV0611TW ( Other Identifier: Company internal )
First Posted: October 6, 2010    Key Record Dates
Last Update Posted: May 19, 2014
Last Verified: May 2014
Keywords provided by Bayer:
Erectile dysfunction
Additional relevant MeSH terms:
Layout table for MeSH terms
Erectile Dysfunction
Sexual Dysfunction, Physiological
Genital Diseases, Male
Sexual Dysfunctions, Psychological
Mental Disorders
Vardenafil Dihydrochloride
Vasodilator Agents
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Urological Agents